Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
复制标题
那匹堡糖蛋白降低了肝细胞癌的癌症干细胞特征。
DOI：
10.3389/fphar.2020.597520
复制
发表时间：
2020
影响因子：
5.6
通讯作者：
Zhang J
中科院分区：
文献类型：
--
作者：
Li Y;Han Q;Zhao H;Guo Q;Zhang J
肝细胞癌（HCC）是原发性肝癌中最常见的类型。癌症干细胞（cancer stem cells，CSCs）是一类具有自我更新和多向分化能力的罕见细胞群，存在于分化程度较高的癌细胞中。肿瘤干细胞与肿瘤复发、耐药和预后不良有关。本研究的目的是确定napabucasin对HCC的疗效，并阐明其潜在的分子机制。Napabucasin通过诱导细胞凋亡和细胞周期阻滞，显著降低体外肝癌细胞的活力。此外，它在体外抑制CSC相关基因表达和球体形成，表明CSC耗尽。纳帕布卡辛的抗肿瘤作用在同种移植荷瘤小鼠模型中也很明显。我们的研究结果提供了科学依据，开展临床试验的纳帕布卡辛作为一种新的治疗肝癌的药物。
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Cancer stem cells (CSCs) are a rare population with self-renewal and multipotent differentiation capacity, and reside among the more differentiated cancer cells. CSCs are associated with tumor recurrence, drug resistance and poor prognosis. The aim of this study was to determine the efficacy of napabucasin against HCC and elucidate the underlying molecular mechanisms. Napabucasin significantly decreased the viability of HCC cells in vitro by inducing apoptosis and cell cycle arrest. In addition, it suppressed CSC-related gene expression and spheroid formation in vitro, indicating depletion of CSCs. The anti-neoplastic effects of napabucasin was also evident in homograft tumor-bearing mouse models. Our findings provide the scientific basis of conducting clinical trials on napabucasin as a new therapeutic agent against HCC.
登录
查看更多内容
影响因子：
5.2
作者：
Beyreis, Marlena;Gaisberger, Martin;Mayr, Christian
通讯作者：
Mayr, Christian
影响因子：
25.7
作者：
Asrani, Sumeet K.;Devarbhavi, Harshad;Kamath, Patrick S.
通讯作者：
Kamath, Patrick S.
影响因子：
13.5
作者：
Kim, JW;Ye, QH;Wang, XW
通讯作者：
Wang, XW
影响因子：
3.7
作者：
Li, Dan;Zhang, Bin;Hu, Chao
通讯作者：
Hu, Chao
影响因子：
--
作者：
Bao, Bin;Ahmad, Aamir;Azmi, Asfar S;Ali, Shadan;Sarkar, Fazlul H
通讯作者：
Sarkar, Fazlul H